Loading stock data…
Theriva Biologics (TOVX)
$0.26+0.01 (+4.08%)
Market ClosedLast close Jun 29
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Theriva Biologics, Inc. in the Healthcare sector is trading at $0.26 with a market capitalization of $13M. Wall Street consensus targets $2.50 (2 analysts), implying a +861.5% move over the next 12 months. The stock is currently near its 52-week low of $0.16, remaining 3.7% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +861.5% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $300,000 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$2.13M↓ | -$2.06M↑ | -$4.44M↑ | -$13.13M↓ | -$4.42M |
| Net Income | -$2.04M↓ | -$2.00M↑ | -$4.36M↑ | -$13.06M↓ | -$4.32M |
Peer Comparison
JNJUNHPFE
Fundamentals
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$12.62M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-139.35%
Volume
Today's trading volume
1.07M
Recent News
Theriva Biologics receives CHMP scientific advice on VCN-01 Phase 3 design
Theriva Biologics (TOVX) announced the receipt of Scientific Advice from the Committee for Medicinal Products for Human Use of the European Medicines Agency on the design of a Phase 3 clinical trial of lead clinical candidate VCN-01 in combination with gemcitabine/nab-paclitaxel standard-of-care chemotherapy for the first-line treatment of metastatic PDAC. The Company has previously reported the results of the VIRAGE randomized, controlled Phase 2b clinical trial, demonstrating that PDAC patient
Theriva Biologics: Q3 Earnings Snapshot
ROCKVILLE, Md. AP) — Theriva Biologics, Inc. TOVX) on Wednesday reported a loss of $4.4 million in its third quarter.
Theriva Biologics: Q2 Earnings Snapshot
ROCKVILLE, Md. AP) — Theriva Biologics, Inc. TOVX) on Monday reported a loss of $13.1 million in its second quarter.